Summary
We're thrilled to share the exciting news of launching our inaugural affiliate in the UK! Our decision to expand into the UK is driven by multiple factors:
Over recent years, we've observed that the UK, despite Brexit, continues to be a highly appealing destination for medical research.
With world-renowned centers of medical innovation like University of Cambridge and University of Oxford, many of our clients are either based in the UK or have significant operations there.
At iliomad Health Data , our mission is to support our clients in the best possible locations, and the UK certainly provides an excellent setting for this.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Vendor GDPR in Clinical Trials: What the IQVIA CNIL Ruling Changes for Sponsors and Healthtech Companies
On 26 May 2026 the CNIL fined IQVIA Operations France EUR 5 million for failures in its two authorised health data warehouses, LRX and EMR. The decision exposes weaknesses in CRO data protection practice that have direct consequences for every pharmaceutical sponsor relying on a CRO to process patient, prescription or trial data. This article unpacks the four areas of failure, explains why pseudonymisation no longer offers the cover many sponsors assume, and sets out a practical oversight checklist for sponsor data controllers.
EU AI Act for Healthcare: What Life Sciences Companies Need to Know before August 2026
EU AI Act 2026 healthcare enforcement requires immediate compliance to avoid penalties.
Navigating US Regulatory Requirements for AI-Powered Medical Devices: A Comprehensive Guide to FDA, HIPAA, and IRB Compliance
US AI medical device compliance requires navigating FDA, HIPAA, IRBs, and consent waivers strategically.
FAQs
Our frequently questions